168 related articles for article (PubMed ID: 12005499)
1. Formation and structure of 1:1 complexes between aryl hydroxamic acids and vanadate at neutral pH.
Bell JH; Pratt RF
Inorg Chem; 2002 May; 41(10):2747-53. PubMed ID: 12005499
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of inhibition of the beta-lactamase of Enterobacter cloacae P99 by 1:1 complexes of vanadate with hydroxamic acids.
Bell JH; Pratt RF
Biochemistry; 2002 Apr; 41(13):4329-38. PubMed ID: 11914079
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of chymotrypsin by a complex of ortho-vanadate and benzohydroxamic acid: structure of the inert complex and its mechanistic interpretation.
Moulin A; Bell JH; Pratt RF; Ringe D
Biochemistry; 2007 May; 46(20):5982-90. PubMed ID: 17469803
[TBL] [Abstract][Full Text] [Related]
4. Complexes formed in solution between vanadium(IV)/(V) and the cyclic dihydroxamic acid putrebactin or linear suberodihydroxamic acid.
Pakchung AA; Soe CZ; Lifa T; Codd R
Inorg Chem; 2011 Jul; 50(13):5978-89. PubMed ID: 21627146
[TBL] [Abstract][Full Text] [Related]
5. Is vanadate reduced by thiols under biological conditions? Changing the redox potential of V(V)/V(IV) by complexation in aqueous solution.
Crans DC; Zhang B; Gaidamauskas E; Keramidas AD; Willsky GR; Roberts CR
Inorg Chem; 2010 May; 49(9):4245-56. PubMed ID: 20359175
[TBL] [Abstract][Full Text] [Related]
6. NMR, CD and MCD studies of vanadate-nucleoside complexes.
Crans DC; Harnung SE; Larsen E; Shin PK; Theisen LA; Trabjerg I
Acta Chem Scand (Cph); 1991 May; 45(5):456-62. PubMed ID: 1873111
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of serine amidohydrolases by complexes of vanadate with hydroxamic acids.
Bell JH; Curley K; Pratt RF
Biochem Biophys Res Commun; 2000 Aug; 274(3):732-5. PubMed ID: 10924345
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of serine beta-lactamases by vanadate-catechol complexes.
Adediran SA; Pratt RF
Biochemistry; 2008 Sep; 47(36):9467-74. PubMed ID: 18702503
[TBL] [Abstract][Full Text] [Related]
9. Chromium(V) complexes of hydroxamic acids: formation, structures, and reactivities.
Gez S; Luxenhofer R; Levina A; Codd R; Lay PA
Inorg Chem; 2005 Apr; 44(8):2934-43. PubMed ID: 15819581
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cobalt(III) hydroxamic acid complexes based on a tris(2-pyridylmethyl)amine scaffold: reactivity toward cysteine methyl ester.
Alimi M; Allam A; Selkti M; Tomas A; Roussel P; Galardon E; Artaud I
Inorg Chem; 2012 Sep; 51(17):9350-6. PubMed ID: 22905650
[TBL] [Abstract][Full Text] [Related]
11. Hydrolytic activity of vanadate toward serine-containing peptides studied by kinetic experiments and DFT theory.
Ho PH; Mihaylov T; Pierloot K; Parac-Vogt TN
Inorg Chem; 2012 Aug; 51(16):8848-59. PubMed ID: 22845736
[TBL] [Abstract][Full Text] [Related]
12. Ternary ligand-zinc-hydroxamate complexes.
Chiu YH; Gabriel GJ; Canary JW
Inorg Chem; 2005 Jan; 44(1):40-4. PubMed ID: 15627358
[TBL] [Abstract][Full Text] [Related]
13. Mononuclear and dinuclear monoperoxovanadium(v) complexes with a hetero ligand. 1.(1) Self-decomposition reaction, detection of reactive oxygen species, and oxidizing ability.
Kanamori K; Nishida K; Miyata N; Shimoyama T; Hata K; Mihara C; Okamoto K; Abe Y; Hayakawa S; Matsugo S
Inorg Chem; 2004 Nov; 43(22):7127-40. PubMed ID: 15500351
[TBL] [Abstract][Full Text] [Related]
14. Sarcoplasmic reticulum calcium ATPase is inhibited by organic vanadium coordination compounds: pyridine-2,6-dicarboxylatodioxovanadium(V), BMOV, and an amavadine analogue.
Aureliano M; Henao F; Tiago T; Duarte RO; Moura JJ; Baruah B; Crans DC
Inorg Chem; 2008 Jul; 47(13):5677-84. PubMed ID: 18510311
[TBL] [Abstract][Full Text] [Related]
15. The oxyvanadium constellation in transition-state-analogue complexes of phosphoglucomutase and ribonuclease. Structural deductions from electron-transfer spectra.
Ray WJ; Post CB
Biochemistry; 1990 Mar; 29(11):2779-89. PubMed ID: 2140698
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, crystal structures, and urease inhibition of an acetohydroxamate-coordinated oxovanadium(V) complex derived from N'-(3-bromo-2-hydroxybenzylidene)-4-methoxybenzohydrazide.
Qu D; Niu F; Zhao X; Yan KX; Ye YT; Wang J; Zhang M; You Z
Bioorg Med Chem; 2015 May; 23(9):1944-9. PubMed ID: 25840795
[TBL] [Abstract][Full Text] [Related]
17. Vanadium(IV,V) complexes of D-saccharic and mucic acids in aqueous solution.
Dornyei A; Garribba E; Jakusch T; Forgo P; Micera G; Kiss T
Dalton Trans; 2004 Jun; (12):1882-91. PubMed ID: 15381996
[TBL] [Abstract][Full Text] [Related]
18. 1H and 51V NMR studies of the interaction of vanadate and 2-vanadio-3-phosphoglycerate with phosphoglycerate mutase.
Liu S; Gresser MJ; Tracey AS
Biochemistry; 1992 Mar; 31(10):2677-85. PubMed ID: 1532128
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of vanadium(IV,V) hydroxamic acid complexes and in vivo assessment of their insulin-like activity.
Haratake M; Fukunaga M; Ono M; Nakayama M
J Biol Inorg Chem; 2005 May; 10(3):250-8. PubMed ID: 15806386
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, X-ray crystal structure, DFT calculations, and catalytic properties of a dioxidovanadium(V) complex derived from oxamohydrazide and pyridoxal: a model complex of vanadate-dependent bromoperoxidase.
Das C; Adak P; Mondal S; Sekiya R; Kuroda R; Gorelsky SI; Chattopadhyay SK
Inorg Chem; 2014 Nov; 53(21):11426-37. PubMed ID: 25321493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
